Trichomoniasis is a sexually transmitted disease (STD) which is caused by the flagellated protozoan parasite passed from one person to another during sex; the parasite usually transmits from a vagina to a penis or from penis to a vagina, and some time, from a vagina to another vagina. Men and women are suffering from trichomoniasis globally. The commonly infected part of the body in women is the lower genital tract (vulva, cervix, vagina, or urethra), while that in men is the inside of the penis (urethra). Trichomoniasis can be asymptomatic or can cause vaginitis, urethritis, or occasionally epididymitis, cystitis, or prostatitis. Burning after urination or ejaculation, itching, redness or soreness of genitals, itching or irritation inside the penis, discomfort while urinating in women, discharge from the penis, dyspareunia, yellow-green, frothy vaginal discharge with soreness of the vulva and perineum, dysuria, urethritis, and purulent area are some of the common symptoms of trichomoniasis. Epididymitis and prostatitis are the major complications of trichomoniasis.
Nucleic acid amplification tests (NAAT), direct fluorescent tests, direct microscopic examination of vaginal secretions, and immunochromographic are the common tests recommended by health care specialists for the diagnosis of trichomoniasis. Trichomoniasis is suspected in men with urethritis, in women with vaginitis, or in their sexual partners. According to a report published by the WHO, trichomoniasis cases are higher in number than chlamydia or gonorrhea cases every year. Trichomoniasis can be treated with metronidazole or tinidazole. Tinidazole is an anti-parasitic drug, while metronidazole is an antibiotic and antiprotozoal medication used for the treatment of trichomoniasis. Metronidazole is available in the market under brand name, Flagyl.
The global trichomoniasis drugs market is expanding significantly due to increase in the incidences of trichomoniasis. Rise in cases of unprotected sex has contributed to the spread of the disease. Low voluntary screening rate for the disease is a major restraint of the market. Awareness about trichomoniasis diagnostic tests is poor in the countries in Africa. Therefore, companies are facing challenges with regard to market penetration in the region. Moreover, several low and middle-income countries depend on government grants for the provision of rapid diagnostic tests in the event of an epidemic. Thus, direct reach to customers is limited in these countries. These factors hamper the growth of the trichomoniasis drugs market in the region.
The global trichomoniasis drugs market can be segmented based on drug type, distribution channel, and region. In terms of drug type, the market can be categorized into metronidazole and tinidazole. In terms of distribution channel, the global trichomoniasis drugs market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies. Based on revenue, the hospital pharmacies segment constituted a significant share of the trichomoniasis drugs market in 2016.
In terms of region, the global trichomoniasis drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the leading market for trichomoniasis drugs. In terms of revenue, the U.S. accounts for the dominant share of the trichomoniasis drugs market in North America. The market in Europe is expanding rapidly due to an increase in the number of patients, especially in the U.K. and Germany. The markets in Asia Pacific and Latin America are projected to expand significantly in the near future. Developing economies such as China and Japan are anticipated to contribute to the growth of the market in the region between 2017 and 2025 due to better health care infrastructure, economic growth, increase in the number of insurance payers, growth of the private health care sector, and increase in awareness among people.
Key players operating in the global trichomoniasis drugs market are Pfizer, Inc., Lupin Ltd., Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Valeant Pharmaceuticals International, Inc., Mission Pharma, Unique Pharmaceutical Laboratories Ltd., and Edenbridge Pharmaceuticals among others.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.